Cargando…

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation

BACKGROUND: Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality-of-life (QoL) data. OBJECTIVE: To co...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Albert H, Tatter, Steven, Rao, Ganesh, Prabhu, Sujit, Chen, Clark, Fecci, Peter, Chiang, Veronica, Smith, Kris, Williams, Brian J, Mohammadi, Alireza M, Judy, Kevin, Sloan, Andrew, Tovar-Spinoza, Zulma, Baumgartner, James, Hadjipanayis, Constantinos, Leuthardt, Eric C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534487/
https://www.ncbi.nlm.nih.gov/pubmed/32315434
http://dx.doi.org/10.1093/neuros/nyaa071
_version_ 1783590322120425472
author Kim, Albert H
Tatter, Steven
Rao, Ganesh
Prabhu, Sujit
Chen, Clark
Fecci, Peter
Chiang, Veronica
Smith, Kris
Williams, Brian J
Mohammadi, Alireza M
Judy, Kevin
Sloan, Andrew
Tovar-Spinoza, Zulma
Baumgartner, James
Hadjipanayis, Constantinos
Leuthardt, Eric C
author_facet Kim, Albert H
Tatter, Steven
Rao, Ganesh
Prabhu, Sujit
Chen, Clark
Fecci, Peter
Chiang, Veronica
Smith, Kris
Williams, Brian J
Mohammadi, Alireza M
Judy, Kevin
Sloan, Andrew
Tovar-Spinoza, Zulma
Baumgartner, James
Hadjipanayis, Constantinos
Leuthardt, Eric C
author_sort Kim, Albert H
collection PubMed
description BACKGROUND: Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality-of-life (QoL) data. OBJECTIVE: To compare 12-mo outcomes from all subjects undergoing LITT for intracranial tumors/neoplasms. METHODS: Demographics, intraprocedural data, adverse events, QoL, hospitalizations, health economics, and survival data are collected; standard data management and monitoring occur. RESULTS: A total of 14 centers enrolled 223 subjects; the median follow-up was 223 d. There were 119 (53.4%) females and 104 (46.6%) males. The median age was 54.3 yr (range 3-86) and 72.6% had at least 1 baseline comorbidity. The median baseline Karnofsky Performance Score (KPS) was 90. Of the ablated tumors, 131 were primary and 92 were metastatic. Most patients with primary tumors had high-grade gliomas (80.9%). Patients with metastatic cancer had recurrence (50.6%) or radiation necrosis (40%). The median postprocedure hospital stay was 33.4 h (12.7-733.4). The 1-yr estimated survival rate was 73%, and this was not impacted by disease etiology. Patient-reported QoL as assessed by the Functional Assessment of Cancer Therapy-Brain was stabilized postprocedure. KPS declined by an average of 5.7 to 10.5 points postprocedure; however, 50.5% had stabilized/improved KPS at 6 mo. There were no significant differences in KPS or QoL between patients with metastatic vs primary tumors. CONCLUSION: Results from the ongoing LAANTERN registry demonstrate that LITT stabilizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real-world registry and comparative to published literature.
format Online
Article
Text
id pubmed-7534487
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75344872020-10-09 Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation Kim, Albert H Tatter, Steven Rao, Ganesh Prabhu, Sujit Chen, Clark Fecci, Peter Chiang, Veronica Smith, Kris Williams, Brian J Mohammadi, Alireza M Judy, Kevin Sloan, Andrew Tovar-Spinoza, Zulma Baumgartner, James Hadjipanayis, Constantinos Leuthardt, Eric C Neurosurgery Research—Human—Clinical Studies BACKGROUND: Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality-of-life (QoL) data. OBJECTIVE: To compare 12-mo outcomes from all subjects undergoing LITT for intracranial tumors/neoplasms. METHODS: Demographics, intraprocedural data, adverse events, QoL, hospitalizations, health economics, and survival data are collected; standard data management and monitoring occur. RESULTS: A total of 14 centers enrolled 223 subjects; the median follow-up was 223 d. There were 119 (53.4%) females and 104 (46.6%) males. The median age was 54.3 yr (range 3-86) and 72.6% had at least 1 baseline comorbidity. The median baseline Karnofsky Performance Score (KPS) was 90. Of the ablated tumors, 131 were primary and 92 were metastatic. Most patients with primary tumors had high-grade gliomas (80.9%). Patients with metastatic cancer had recurrence (50.6%) or radiation necrosis (40%). The median postprocedure hospital stay was 33.4 h (12.7-733.4). The 1-yr estimated survival rate was 73%, and this was not impacted by disease etiology. Patient-reported QoL as assessed by the Functional Assessment of Cancer Therapy-Brain was stabilized postprocedure. KPS declined by an average of 5.7 to 10.5 points postprocedure; however, 50.5% had stabilized/improved KPS at 6 mo. There were no significant differences in KPS or QoL between patients with metastatic vs primary tumors. CONCLUSION: Results from the ongoing LAANTERN registry demonstrate that LITT stabilizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real-world registry and comparative to published literature. Oxford University Press 2020-09 2020-04-21 /pmc/articles/PMC7534487/ /pubmed/32315434 http://dx.doi.org/10.1093/neuros/nyaa071 Text en © Congress of Neurological Surgeons 2020. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Research—Human—Clinical Studies
Kim, Albert H
Tatter, Steven
Rao, Ganesh
Prabhu, Sujit
Chen, Clark
Fecci, Peter
Chiang, Veronica
Smith, Kris
Williams, Brian J
Mohammadi, Alireza M
Judy, Kevin
Sloan, Andrew
Tovar-Spinoza, Zulma
Baumgartner, James
Hadjipanayis, Constantinos
Leuthardt, Eric C
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
title Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
title_full Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
title_fullStr Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
title_full_unstemmed Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
title_short Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
title_sort laser ablation of abnormal neurological tissue using robotic neuroblate system (laantern): 12-month outcomes and quality of life after brain tumor ablation
topic Research—Human—Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534487/
https://www.ncbi.nlm.nih.gov/pubmed/32315434
http://dx.doi.org/10.1093/neuros/nyaa071
work_keys_str_mv AT kimalberth laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT tattersteven laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT raoganesh laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT prabhusujit laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT chenclark laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT feccipeter laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT chiangveronica laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT smithkris laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT williamsbrianj laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT mohammadialirezam laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT judykevin laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT sloanandrew laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT tovarspinozazulma laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT baumgartnerjames laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT hadjipanayisconstantinos laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation
AT leuthardtericc laserablationofabnormalneurologicaltissueusingroboticneuroblatesystemlaantern12monthoutcomesandqualityoflifeafterbraintumorablation